Matthew Stephen Block

16PUBLICATIONS
134CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Immunogenetics (incl. genetic immunology)Proteins and peptidesMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Nov 10, 2025
A Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of a Folate Receptor Alpha Vaccine in Patients with Triple-Negative Breast Cancer.

Keith L Knutson, Hala Abu-Fares, Patricia Keating

|Apr 15, 2025
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial.

Matthew S Block, Garth D Nelson, Jun Chen

|Mar 14, 2025
Plasma exchange and radiation resensitize immunotherapy-refractory melanoma: a phase I trial.

Jacob J Orme, Henan Zhang, Prashanth Lingamaneni

|Feb 05, 2025
The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial.

Matthew Stephen Block, James Hugo Armstrong Clubb, Johanna Mäenpää

|Apr 30, 2024
Identification and Characterization of Immune Checkpoint Inhibitor-Induced Toxicities From Electronic Health Records Using Natural Language Processing.

Hannah Barman, Sriram Venkateswaran, Antonio Del Santo

|Mar 26, 2024
A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies.

Eleftheria Kalogera, Wendy K Nevala, Heidi D Finnes

Pageof 3

Frequent Collaborators

5 joint publications

Robert R McWilliams

4 joint publications

Lisa A Kottschade

3 joint publications

Evidio Domingo-Musibay

3 joint publications

Haidong Dong